유럽 ​​첨단 상처 치료 시장 – 2023-2030

Market Overview
Europe advanced wound care size was valued at US$ 2.97 billion in 2022 and is estimated to reach US$ 4.37 billion, growing at a CAGR of 5.0% during the forecast period (2023-2030).
Advanced wound care comprises products that treat acute and chronic wounds, such as ulcers, burns, and post-operative wounds. The products, such as film and foam dressings, hydrogels, alginates, and hydrocolloids, keep the damage hydrated to encourage healing without occluding the wound.
Market Dynamics
The growth of the market is majorly driven by the increasing aging population, advancements in technologies, raising cases of diabetics, increasing patient awareness, and raising patient healthcare expenditure are the major factors driving the market growth.
The growing geriatric population and the raising cases of people with diabetes are predicted to drive Europe’s market growth.
According to the Eurostat, in 2021, more than one-fifth, i.e., 20.8 %, of the EU population was aged 65 and over, and the percentage of people was 80 or over. The EU's population is anticipated to increase two-and-a-half-fold from 6.0 % in 2021 to 14.6 % in 2100. Also, according to the World Economic Forum, the European Union and other regions across the globe are expected to face rapidly aging populations this century. Across 30% of the EU population is predicted to be 65 or older by 2100. In 2021, the EU's dependency ratio was 32, which is expected to reach 57 by 2100, i.e., for every 100 working-age people, there were 57 elderly people.
Moreover, the growing diabetes cases in Europe are also boosting the market growth in the forecast period. For instance, according to the IDF Diabetes Atlas, an estimated 61 million adults were living with diabetes in the IDF Europe Region in 2021, and the region has the most elevated number of adolescents and children with type 1 diabetes, accounting for about 295,000. In addition, according to the WHO Europe, diabetes impacts over 52 million people and a growing percentage of the population in multiple European countries. Also, approximately 15% of people with diabetes experience a foot ulcer at some moment in their lives, and in numerous cases, the foot requires to be amputated. Therefore, about 100 000 diabetes-related non-traumatic lower limb amputations are performed annually in Europe. Thus, from the mentioned data, it is estimated that the growing geriatric population and diabetic cases in Europe will drive the advanced wound care market growth during the forecast period.
The high cost associated with wound care products is restraining the growth of Europe’s advanced wound care market.
However, the high cost associated with wound care products is one of the major factors hindering the market growth. For instance, according to the National Health Service (NHS) in the United Kingdom, venous leg ulcers (VLUs), pressure ulcers (PUs), and DFUs are among the costliest wounds in the UK. According to a UK-based study, the cost of this wound care was estimated at over £4.5 billion (5.72 USD billion), not accounting for the care of comorbidities or costs undertaken by patients themselves. No robust or cost-effective dressing is available except antimicrobial dressings (silver, iodine, or honey), which are preferred over nonmedicated dressings to heal chronic wounds.
COVID-19 Impact.
The COVID-19 pandemic during the initial period transformed the European region's medical care. The raised stress because of the increasing rate of hospitalization of COVID-19 patients led to the re-profiling of multiple infirmaries and units for treating COVID-19 patients. Therefore, considerable elective surgery procedures were either canceled or delayed to reserve or redirect the available limited capacities and resources for COVID-19 patient care, lowering the demand for wound care products. However, the sedentary lifestyle led to an increase in the incidence of diabetes, contributing to market growth.
Segment Analysis
The foam dressing product segment is expected to have a greater hold of Europe’s advanced wound care market during the forecast period (2032-2030).
Foam dressings are highly absorptive dressings utilized for wound care. Foam dressings require less frequent changes than other kinds of dressings. The benefit of foam dressings is that foam support holds a moist wound surrounding. Moreover, the foam cushions the wound, and peri-wound area from further trauma and delivers thermal insulation for wounds. Again, these dressings are comfortable to remove and render less trauma, widely used in most wound dressings, preferably lower extremities chronic ulcers, particularly those related to diabetes, venous disease, or arterial disease.
The increasing new product introductions into the market are estimated to ensure the dominance of foam dressings over the Europe advanced wound care market throughout the forecast period. For instance, in November 2020, Advanced Medical Solutions, an expert enterprise in surgical and advanced wound care, was granted a Conformitè Europëenne (CE) mark for its Silicone PHMB Foam Dressing, a polyurethane foam impregnated with Polyhexamethylene Biguanide and an atraumatic perforated silicone wound contact layer. Furthermore, initiatives aimed towards reducing the cost of raw materials, such as In October 2021, Germany's Covestro began the European Union (EU) project to research the recycling of polyurethane (PU) foams. The Circular Foam project concerns 22 members from nine EU countries. Therefore, from the abovementioned factors, foam dressings will be estimated to dominate Europe's advanced wound care market throughout the forecast period.
Geographical Analysis
Germany is expected to dominate the Europe advanced wound care market.
The increasing need for advanced wound care owing to the increased number of surgical procedures performed and various market developments in Germany are boosting the regional market growth at a high CAGR. For instance, according to the German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery, there were about 29,444 isolated coronary artery bypass grafting operations carried out, around 35,469 isolated heart valve surgeries, and roughly 843 assist device implantations documented in Germany. Also, the number of solitary heart transplants in Germany has surged to 340, a 2.1 percent increase over the previous year.
Moreover, according to the Federal Statistics Office of Germany data released in August 2022, more than 2,314,938 accidents were registered in Germany in 2021, with about 325,691 individuals wounded in the accidents. Likewise, the growing cases of diabetes in this region also contribute to the regional market growth. For example, according to the International Diabetic Federation, the total adult population in Germany in 2022 was around 62,027,700, and the total cases of diabetes in adults were about 6,199,900 making the prevalence of diabetes in german adults to be approximately 10.0%. In addition, according to the German Centers for Health Research, in Germany, over 8.5 million people have diabetes, about 2 million people live with undiagnosed diabetes, and the number of people with type 2 diabetes in Germany will continue to rise over the next twenty years. Researchers at the DZD estimate that up to twelve million people could suffer from metabolic disease by 2040.
Furthermore, the increasing market developments in the German advanced wound care market also contribute to its growth in the forecast period. For instance, in June 2021, Bactiguard and German company Schülke & Mayr GmbH (schülke) formed an exclusive distribution agreement for Bactiguard’s scope of wound care products to German hospitals. schülke is among the leading global manufacturers and distributors of infection prevention and hygiene solutions. Similarly, in September 2022, Evonik agreed with the medical technology consulting and sales company Coopmed to distribute the wound dressing epicite. Ther Coopmed will distribute epicite exclusively to the German market for chronic wound management. The wound dressing epicite is one of the products from the portfolio of JeNaCell, a company based in Jena, Germany, which Evonik acquired in 2021. Thus, from the mentioned data, it is estimated that Germany will dominate the Europe advanced wound care market throughout the forecast period.
Competitive Landscape
Europe advanced wound care market is competitive due to the increasing demand and increasing market developments of new market players. The key players operating in the Europe advanced wound care market hold most of the market share examples are B. Braun Melsungen AG, Integra Lifesciences, Cardinal Health Inc., Molnlycke Health Care, Smith & Nephew, Coloplast AS, 3M Company, ConvaTec Group PLC, Paul Hartmann AG, and Medtronic PLC, among others. The key players are embracing various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the European Advanced Wound Care market. For instance, in April 2022, Germany-based home care provider for patients with chronic wounds, Wundex, a capiton portfolio company, acquired ELLIPSA, a wound care specialist with headquarters in Regensburg (Bavaria), a second center of operations in Munich.
3M Company
Overview:
3M is a leading manufacturer all over the world. It has a global presence and is headquartered in Saint Paul, Minnesota, the United States, which was founded on June 13, 1902. 3M deals with 60,000 various products under many brands; the product categories are adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products, electronic circuits, healthcare software and optical films.
Product Portfolio:
The Company’s portfolio has 3M V.A.C. Ulta Therapy Unit: 3M V.A.C. Ulta Therapy System is a combined wound managing system that delivers four separate and distinct wound treatment alternatives in the comfort of one device: V.A.C. Therapy, Veraflo Therapy, Prevena Therapy and AbThera Therapy.
Europe advanced wound care report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.